
GSK Nuvalent Acquisition: ROS1/ALK NSCLC TKI Pipeline
Analyze GSK’s $10.6B Nuvalent acquisition. Learn about zidesamtinib & neladalkib, their clinical trial data, and the ROS1/ALK NSCLC competitive landscape.

Analyze GSK’s $10.6B Nuvalent acquisition. Learn about zidesamtinib & neladalkib, their clinical trial data, and the ROS1/ALK NSCLC competitive landscape.
© 2026 IntuitionLabs. All rights reserved.